Dynamic Technology Lab Private Ltd Increases Stake in Sangamo Therapeutics Inc (SGMO)

Share on StockTwits

Dynamic Technology Lab Private Ltd lifted its position in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 171.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,384 shares of the biopharmaceutical company’s stock after acquiring an additional 25,483 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Sangamo Therapeutics were worth $573,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its position in shares of Sangamo Therapeutics by 193.6% in the 1st quarter. Cubist Systematic Strategies LLC now owns 65,087 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 42,917 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Sangamo Therapeutics by 331.9% in the 1st quarter. Prudential Financial Inc. now owns 505,536 shares of the biopharmaceutical company’s stock worth $9,605,000 after buying an additional 388,480 shares during the last quarter. Creative Planning grew its stake in shares of Sangamo Therapeutics by 192.1% in the 2nd quarter. Creative Planning now owns 30,413 shares of the biopharmaceutical company’s stock worth $432,000 after buying an additional 20,000 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Sangamo Therapeutics by 372.0% in the 1st quarter. JPMorgan Chase & Co. now owns 98,888 shares of the biopharmaceutical company’s stock worth $1,880,000 after buying an additional 77,937 shares during the last quarter. Finally, Element Capital Management LLC purchased a new stake in shares of Sangamo Therapeutics in the 1st quarter worth approximately $240,000. 63.97% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics stock opened at $14.85 on Friday. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $1.47 billion, a P/E ratio of -21.21 and a beta of 2.95. Sangamo Therapeutics Inc has a twelve month low of $11.30 and a twelve month high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million for the quarter, compared to analysts’ expectations of $21.43 million. During the same quarter in the prior year, the business posted ($0.17) earnings per share. The business’s revenue for the quarter was up 159.6% on a year-over-year basis. analysts expect that Sangamo Therapeutics Inc will post -0.69 EPS for the current fiscal year.

In other Sangamo Therapeutics news, Director H Stewart Parker bought 2,000 shares of the business’s stock in a transaction on Friday, September 7th. The shares were acquired at an average cost of $13.52 per share, for a total transaction of $27,040.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the stock in a transaction on Friday, July 6th. The shares were sold at an average price of $15.80, for a total value of $79,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,000 shares of company stock worth $367,900. Company insiders own 1.20% of the company’s stock.

Several research firms recently weighed in on SGMO. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Bank of America began coverage on Sangamo Therapeutics in a research note on Wednesday, June 20th. They issued a “buy” rating and a $24.00 price target on the stock. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Wedbush restated a “hold” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, August 9th. Finally, ValuEngine downgraded Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $21.00.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.